Dr. Apolo on Study of Cabozantinib Plus Nivolumab and Ipilimumab in Urothelial Carcinoma
Andrea B. Apolo, MD
Andrea B. Apolo, MD, chief of bladder cancer section, National Cancer Institute, discusses a phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma (mUC) and other genitourinary tumors.
In this study, the combinations of cabozantinib/nivolumab and cabozantinib/nivolumab/ipilimumab were evaluated for safety and clinical activity. Both combinations were well tolerated and responses were seen at all dose levels, with the recommended doses at 40 mg cabozantinib/3 mg nivolumab and 40 mg cabozantinib/3 mg nivolumab/1 mg ipilimumab.
In addition to responses in patients with mUC, rare tumors such as basaloid squamous cell carcinoma, urachal, and penile cancer also showed significant responses.